Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 28.42M shares rose 4.8% year over year, ahead of the +1.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.8% from the prior quarter. Over 3 fiscal years it compounded at +1.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.8% holds above the trailing-twelve-month pace of +1.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
28.42M+3.8% QoQ
Last fiscal yearDec 2025
27.39M+1.4% YoY
LTMMar 2026
27.53M+1.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.8%——
1 year+1.4%——
3-year CAGR+1.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
27.39M USD
Year-over-year change
+1.4%
4-year CAGR
+1.0%

Weighted Avg Shares vs competitors

How ARCT compares with its peers on the latest reported figures

  • ARCT's LTM Mar 2026 weighted avg shares of 27.53M shares is the lowest of the 11 companies compared; the peer median is 108.11M shares.
  • Its year-over-year change of +1.8% is the 9th highest of 10, against a peer median of +12.7%.
  • Over three fiscal years its annual growth of +1.2% compares with a peer median of +15.7%.
ARCT Competitors Peer median
Weighted Avg Shares for ARCT and competitors
Company Period LTM YoY 3-year CAGR
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
ABUSArbutus Biopharma CorporationLTM Mar 2026192.17M +2.0%+8.3%
NVAXNovavax, Inc.LTM Mar 2026162.41M +3.2%+27.5%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+1.5%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
PRQRProQR Therapeutics N.V.LTM Mar 2026104.77M +19.6%+13.7%
VALNValneva SELTM Mar 202683.89M +18.5%+13.4%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
BNTCBenitec Biopharma Inc.LTM Mar 202643.27M +112.6%+166.1%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+1.2%
Peer median (excluding ARCT) 108.11M+12.7%+15.7%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.36M205.76M157.75M138.39M67.22M
Cost of Revenue00003.03M
Gross Profit12.36M205.76M157.75M138.39M64.2M
Gross Margin100.0%100.0%100.0%100.0%95.5%
Research & Development173.76M147.75M192.13M195.16M112.21M
Selling, General & Admin41.45M46.07M52.87M52.82M46.08M
Operating Expenses215.21M193.58M235.95M234.06M139.15M
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
EBITDA(199.81M)15.17M(24.17M)(77.4M)(62.76M)
EBITDA Margin-1616.7%7.4%-15.3%-55.9%-93.4%
Operating Income(202.85M)12.18M(78.21M)(95.67M)(74.96M)
Operating Margin-1641.3%5.9%-49.6%-69.1%-111.5%
Interest Income753K2.58M17.36M15.2M10.1M
Interest Expense2.67M3M767K00
Other Income / Expenses(822K)(1.53M)50.32M14.72M9.17M
Income Before Tax(203.67M)10.64M(27.89M)(80.95M)(65.78M)
Pre-Tax Margin-1648.0%5.2%-17.7%-58.5%-97.9%
Income Tax Expense01.3M1.84M(4K)0
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Net Margin-1648.0%4.5%-18.8%-58.5%-97.9%
EPS (Basic)(7.74)0.35(1.12)(3.00)(2.40)
EPS (Diluted)(7.74)0.35(1.12)(3.00)(2.40)
Weighted Avg Shares26.32M26.45M26.63M27M27.39M
Weighted Avg Shares (Diluted)26.32M27.09M26.63M27M27.39M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.